key: cord-1054540-wl7wc6h8
authors: Hu, Wenjuan; Chang, Lu; Ke, Changqiang; Xie, Yuanchao; Shen, Jingshan; Tan, Bo; Liu, Jia
title: Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS
date: 2020-11-30
journal: J Pharm Biomed Anal
DOI: 10.1016/j.jpba.2020.113806
sha: 28ea42d20e586a982650b9f82309bbf4764a6dba
doc_id: 1054540
cord_uid: wl7wc6h8

Remdesivir is a prodrug of the nucleotide analogue and used for COVID-19 treatment. However, the bioanalysis of the active metabolites remdesivir nucleotide triphosphate (RTP) and its precursor remdesivir nucleotide monophosphate (RMP) is very challenging. Herein, we established a novel method to separate RTP and RMP on a BioBasic AX column and quantified them by high-performance liquid chromatography-tandem mass spectrometry in positive electrospray ionization mode. Stepwise, we optimized chromatographic retention on an anion exchange column, improved stability in matrix through the addition of 5,5’-dithiobis-(2nitrobenzoic acid) and PhosSTOP EASYpack, and increased recovery by dissociation of tight protein binding with 2% formic acid aqueous solution. The method allowed lower limit of quantification of 20 nM for RMP and 10 nM for RTP. Method validation demonstrated acceptable accuracy (93.6% – 103% for RMP, 94.5% – 107% for RTP) and precision (RSD < 11.9% for RMP, RSD < 11.4% for RTP), suggesting that it was sensitive and robust for simultaneous quantification of RMP and RTP. The method was successfully applied to analyze RMP and RTP in mouse tissues. In general, the developed method is suitable to monitor RMP and RTP, and provides a useful approach for exploring more detailed effects of remdesivir in treating diseases.

RMP and RTP in different mouse tissues. Moreover, we successfully applied it to measure the exposure of several tissues to RMP and RTP after a single oral administration of RDV in mice.

RDV (purity ≥ 98%), RMP (purity of 93%), and RTP (purity of 98%) were synthesized as previously reported [6, 18] . The structure and purity of each compound were identified by NMR and HPLC-UV. RN (purity of 98%) was purchased from Target Molecule Corp. (Boston, MA, USA). Adenosine triphosphate (ATP, purity of 99%), uridine triphosphate (UTP, purity of 96%), 13 C, 15 

The development and validation processes for quantification of RMP and RTP were conducted in an ultra-performance liquid chromatography coupled triple-quadrupole mass spectrometry (UPLC-MS/MS) instrument, which comprised an AQUITY UPLC system with a thermostatted autosampler and an ultrahigh performance binary pump 

The stabilization procedure was optimized in liver homogenates under different conditions at 15 and 30 min. A 50 μL liver homogenate was immediately added to a 1.5 mL polyethylene tube containing 5 μL RMP or RTP solution (10 μM in water) and different stabilizing agents as follows: (a) 10 μL 100 mM BNPP; (b) 10 μL 500 mM DTNB; (c) 5 μL PhosSTOP solution (the solution was prepared by dissolving one piece of PhosStop tablet into 1 mL waters, and the spiked sample concentration of PhosSTOP was referred to as 10% PhosSTOP); or (d) 10 μL 500 mM DTNB and 5 μL PhosSTOP solution. Then a 150 μL 2% FA aqueous solution was added to the prepared tube for further solid-phase extraction (SPE). For comparison, another 50 μL liver homogenate was added to a 1.5 mL polyethylene tube with 500 μL of ACN-MeOH (1:1, v/v) to precipitate protein and inactivate enzymes thoroughly, and then RMP or RTP solution was added into the supernatant. Next, after SPE, the samples were analyzed.

Binding studies between human serum albumin (HSA, purity ≥ 98%, Sigma-Aldrich) and RTP, ATP, or UTP were conducted under native conditions using an electrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry (ESI-FT-ICR MS) method as previously reported [19] . The commercial HSA was purified five times by buffer exchange with 10 mM NH4Ac (pH 6.0) buffer in an Amicon Ultra 30k cellulose membrane filter (Merck). Purified HSA (3 µM) and different concentrations The charges stated 17 + to 19 + were isolated and used to calculate the intensity ratios of the free HSA to the HSA-nucleotide complex. Mass spectra data were deconvoluted using the SNAP2 function in DataAnalysis 5.2 software (Bruker Daltonics, Germany). The equilibrium dissociation constant (KD) was calculated using a nonlinear regression in GraphPad Prism 8.2.1.

The recovery was optimized using liver homogenate under several different conditions, including 2% FA in H2O, 3% FA in H2O, H3PO4, 10 M NH4Ac, 20 J o u r n a l P r e -p r o o f mg•mL -1 AgNO3, 1 M Boc-Lys(Boc)-OH, 10 mM TCEP, 20% Invitrosol, 50 μL liver homogenate, which was immediately added to a 1.5 mL polyethylene tube containing 5 μL RMP or RTP solution and prepared by 150 μL aforementioned regents, respectively. 

To minimize experimental errors resulting from instability, the RMP and RTP working solutions were freshly prepared before use. For the establishment of standard curves, J o u r n a l P r e -p r o o f RMP and RTP working solutions were serially diluted with liver homogenate to final concentrations of 20, 50, 100, 200, 500, 1,000, 4,000, and 10,000 nM for RMP and 10, 20, 50, 100, 200, 500, 1,000, 4,000, and 10,000 nM for RTP, spiked with 5 μL of IS (10 μM in water), and prepared as described above in the sample preparation section. The calibration curves were evaluated by plotting the absolute peak-area ratios of the analyte to the IS area against the corresponding RMP and RTP concentrations. The linearity of RMP and RTP to IS peak area ratio versus the theoretical concentration was verified using 1/x 2 -weighted linear regression. The precision and accuracy for intra-and inter-day analyses of the RMP and RTP were performed by quality control (QC) samples at concentrations of 30, 300 and 7,500 nM. The QC samples were prepared and extracted as described in standard samples.

To assess intra-day precision and accuracy, six replicates were prepared and analyzed on the same day. To assess inter-day precision, samples were analyzed for three consecutive days. The precision was evaluated by recoveries and intra-and inter-day relative standard deviations (RSDs). The accuracy was calculated from the detected concentrations divided by the theoretical concentration of RMP and RTP. Sensitivity was assessed by the lower limit of quantitation (LLOQ). Matrix effects are analyzed by comparison of extracted blank matrix spiked with analyte and a dilution of analytes at the same concentration in solvent used for injection. In addition, partial validation including accuracy, precision, recovery, matrix, and etc., were conducted in kidney and lung homogenates with respective QC samples as the same concentrations as those of liver homogenates.

J o u r n a l P r e -p r o o f 12 The tissue concentrations were calculated by the equation as follows:

Chomogenate is the tissue homogenate concentration (nM), V is the tissue homogenate volume (mL), and M is the weight of the tissue sample (g).

Caesarean Derived-1 (CD-1) mice (male, 7 -8 weeks, 18 -22 g) were purchased from Shanghai Super-B&K Laboratory Animal Co., Ltd. (Shanghai, China). Twentyfour CD-1 mice were randomly divided into four groups (n = 6) and allowed free access to water but fasted for 12 hours prior to the experiment. All mice received a single oral administration of 100 mg•kg -1 RDV, which was dissolved in DMSO-0.5% 

RMP, RTP, and 13 C, 15 Kinetex Polar C18 column (Phenomenex), were tried using common mobile phase, but failed to obtain satisfactory retention for RTP (Figs. 3c and 3d). In addition to the above tested methods, ion-pairing chromatography is another approach to improve the retention of highly hydrophilic compounds [15, 20] . However, the ion-pairing reagents in the mobile phase could cause high ion suppression for MS response.

Alternatively, we further chose an anion exchange column (Biobasic AX, 2.1×50 mm, 4.6 μm, Thermo Fisher) with MS compatible mobile phase [21] , which could retain highly polar compounds by adjusting the pH conditions. Using solvents of 10 mM NH4Ac in ACN-H2O (3:7, v/v) at different pH values, several LC conditions were compared (Figs. 3e and 3f) . We finally achieved the desired retention and peak shape using a gradient program, with which the retention times of RMP and RTP were 1.38 min and 2.26 min, respectively. J o u r n a l P r e -p r o o f

Regarding biological sample preparation, protein precipitation (PPT), liquid-liquid extraction (LLE) and SPE were the most commonly used approaches. Owing to the extremely high hydrophilicity of phosphates, water-immiscible organic solvents could not extract RMP and RTP from tissue homogenate. Therefore, LLE could not be applied in sample preparation for phosphate bioanalysis. PPT using ACN, MeOH, acetone, or the other organic solvents is convenient and efficient for removing large amounts of protein from biological matrices. We attempted this approach, however, serious ion suppression was observed due to the co-elution of endogenous components (data not shown). Thus, SPE was used for further development.

Due to the high polarity of RMP and RTP, reversed C18 or C8 packing materials could not be used for the separation of analytes and other endogenous interferences. On account of the strong acidity of the phosphate group, the ion-exchange resin was evaluated. Oasis WAX (Waters) SPE cartridge was packed with anion-exchange sorbent, which could sufficiently absorb analytes under low pH and release them under high pH [14, 22, 23] . We carefully optimized the balancing, loading and elution procedures. The pH of the balancing solvent was optimized as 4.5 with 5 mM NH4Ac buffer. The elution solvent was optimized as 10% NH3·H2O in ACN-MeOH (6:4, v/v).

With the optimized balancing and elution procedures, RMP and RTP in solution could achieve good recovery in any acid loading solvents. Meanwhile, using this SPE procedure, the sample was purified such that under the HPLC conditions used, there J o u r n a l P r e -p r o o f were no observed matrix effects.

Generally, the nucleotide analogue drugs have very poor stability in biological samples [16, 21] . As shown in Fig. 1 Throughout the pretreatment process, reaction on ice is a normal approach for unstable compounds. Unfortunately, we observed minor resistance to degradation for RDV, RDP, and RTP when placed on ice (Fig. 4a) . Specifically, the ice condition had little effect on both RDV and RTP degradation, which almost completely degraded in 5 min both on ice, as well as at room temperature. Then, several stabilizing agents, including organic solvent (ACN-MeOH, 1:1, v/v), carboxylesterase inhibitors (BNPP and DTNB), and phosphatase inhibitor cocktail (phosSTOP), were investigated alone or in combination (Fig. 4b) . Among them, the combination of DTNB and phosSTOP exhibited the best suppression effect for degradation of RDV, RMP and RTP. Thus, 0.5 M DTNB and 10% phosSTOP mixture was used as the stabilizer during sample preparation.

However, a confusing phenomenon was also observed that RTP showed very low concentrations in the ACN-MeOH treated samples. Theoretically, organic solvent should thoroughly inhibit the activities of metabolic enzymes. After further J o u r n a l P r e -p r o o f investigation, we found it was caused by the extremely low recovery of RTP in organic solvent treated samples.

Because extremely low recovery of RTP was noticed during method development, we suspected the coprecipitation of RTP and protein. To further investigate the hypothesis and discover the solution, we evaluated the affinity between RTP and albumin and optimized the sample preparation procedure accordingly.

ATP was reported to have a very tight serum albumin binding [24] , while RTP, as its analogue, could have similar properties. The affinity between RTP and HSA was evaluated by the FT-ICR MS method (Table 1 and Fig. 5 ). The KD of RTP with HSA was 0.839 μM and close to that of ATP (0.471 μM), which confirmed a high serum albumin binding affinity for RTP. UTP with a much different nucleotide showed a much lower binding affinity. The tight protein binding of RTP could cause coprecipitation when biological samples were precipitated using organic solvent and then a consequent low recovery.

To overcome the issue of tight protein binding, several protein dissociation approaches were carefully evaluated, including acid dissociation (FA and phosphoric acid), salting-out (NH4Ac), disulfide bond reduction (TCEP), thioester cleaving J o u r n a l P r e -p r o o f (AgNO3), tyrosine residue blocking (Boc-LYS(Boc)-OH), and protein solubilizing (Invitrosol). The details and results are shown in Fig. 6 . Eventually, 1.5% FA aqueous solution was used as the loading solvent, with which we achieved relatively high recoveries for RMP and RTP.

The calibration curves were linear over the concentration ranges of 20 to 10,000 nM and 10 to 10,000 nM for RMP and RTP, respectively. In the assessment, the accuracy values of the back-calculated concentrations of calibration standards including the LLOQs from three different runs ranging from 94.4% to 101% and 95.3% to 113% for RMP and RTP, respectively. For all concentrations, RMP and RTP showed excellent precision with RSDs less than 2.6% and 6.2%, respectively. The determination coefficients (r 2 ) were more than 0.99 across all the analytes in 3 runs. The typical equations of RMP and RTP in tissue homogenate were y = 0.000319 X + 0.00219 (r 2 = 0.9903) and y = 0.000678 X -0.00450 (r 2 = 0.9929), respectively.

MRM chromatograms of blank sample were compared with that at the LLOQ. The typical chromatograms are shown in Fig. 7 . Under the optimized LC-MS/MS condition, no significant interferences were observed at the retention times of the analytes.

Accuracy and precision were evaluated by six replicate analyses of the LLOQ (10 nM and 20 nM for RMP and RTP, respectively), low (30 nM for both RMP and RTP), medium (300 nM for both RMP and RTP) and high QC (7,500 nM for both RMP and RTP) levels in three separate analytical runs. The acceptance criteria of accuracy and precision were 85%-115% and less than 15% for all concentration levels except for LLOQ. The acceptance criteria of accuracy and precision for LLOQ were 80% -120% and less than 20%.

The results of intra-and inter-day accuracy and precision based on LLOQ and QC samples are summarized in Table 2 . The accuracy for RMP ranged from 93.6% to 103%. The RSD of intra-assay precision for the RMP was < 6.3%, while the RSD of inter-assay precision was < 11.9%. The accuracy for RTP ranged from 94.5% to 107%. The RSD of intra-assay precision for the RTP was < 6.2%, while the RSD of inter-assay precision was < 11.4%. The method was determined to be reliable and reproducible as all the accuracy and the intra-and inter-day precision values were within acceptable ranges.

The matrix effect ranged from 97.0 to 97.1% for RMP and 94.9 to 103% for RTP. The matrix effect of IS at 1,000 nM was 101%. The variation (RSD) values of the matrix effects for all the analytes and IS were <11.7%. Thus, ionization enhancement or suppression was negligible after sample extraction under the current conditions.

The validated method was applied to the tissue distribution study of RMP and RTP after a single oral dose of remdesivir at 100 mg•kg -1 in mice (Fig. 8) . The main pharmacokinetic parameters are listed in Table 4 (Fig. 8) . In the three tissues RMP showed a much higher exposure than RTP. Among the three tissues liver was most abundant and followed by kidney for both RMP and RTP.

Nucleoside analogues are normally prodrugs that require intracellular phosphorylation to active triphosphate nucleotide metabolites (ATNs) for their therapeutic effects. Numerous assays have been described for the determination of those nucleotides or nucleotide analogues, such as electrochemical method [25] , fluorescence spectrometry [26, 27] and LC-MS [14-17, 20-22, 28-30] . Although reversed phase LC-MS/MS is considered to be the most commonly used tool in bioanalysis, it is still very challenging to measure ATNs and related mono/di-phosphate nucleotide metabolites due to their instability, high hydrophilicity, confusing endogenous interferences, as well as very low concentrations in blood and tissues [31] . To date, there is still a lack of detailed methods for direct determination of RTP and its precursor form RMP in biological matrices, which might hamper therapeutic studies of RDV in COVID-19.

In the current study, facing these vital issues, we optimized the LC-MS/MS method step by step. Initially, similar to the general process for method development of nucleotide compounds, we modified the MS and LC conditions and finally achieved a desired MS response (positive ion mode) and a satisfactory LC retention (separation on an ion-exchange chromatography column). Then, regarding two key challenges of the current method, i.e., stability and recovery, we performed a careful investigation and fit-to-purpose optimization.

Considering stability, degradation is normally the most serious issue for most unstable analytes. However, for the analytes in the current study, especially for RMP, the situation was more complicated. On one hand, RMP could degrade into RN; on the other hand, it could be generated from RDV, as well as RTP [32] . Regarding tissue samples, the preparation procedure contained several steps including homogenization and SPE and thus took some time. Consequently, to obtain accurate concentrations, degradation of all RDV, RMP and RTP should be prevented in tissue sample preparation. We optimized the pretreatment processes in terms of temperature and stabilizing agents, which included organic solvent (ACN-MeOH, 1:1, v/v), carboxylesterase inhibitors (BNPP and DTNB), and phosphatase inhibitor cocktail (phosSTOP). Only low temperature could not prevent degradation, while combined J o u r n a l P r e -p r o o f esterase and phosphatase inhibitors could significantly improve stability. Finally, using the modified conditions, the samples were stable for 60 min, which provided an adequate period for sample preparation.

In the experiment, we found very low recovery of RTP by protein precipitation (MeOH or ACN), which is normally used in pretreatment of ATNs in biological matrix [33] . Regarding the issue of RTP's low recovery, the main reason was investigated and confirmed to be protein-analyte coprecipitation based on the results of protein binding affinity. To resolve this problem, various protein denaturing reagents, such as acid dissociation (FA and phosphoric acid), salting-out (NH4Ac), disulfide bond reduction (TCEP), thioester cleaving (AgNO3), tyrosine residue blocking (Boc-LYS(Boc)-OH), and protein solubilizing (Invitrosol), were tested and compared. Among them, FA treatment showed the highest recovery and was chosen for sample preparation. Meanwhile, RDV is an ester and both RMP and RTP are phosphates, all of which are unstable in either acidic or basic conditions. Thus, their stabilities were monitored during the evaluation of protein denaturing. Using this optimized protein denaturing coupled with the SPE procedure, we achieved a desired recovery for both RMP and RTP.

In summary, targeting several challenges, we performed a stepwise optimization, set up several approaches to overcome the key issues, and eventually achieved a modified strategy. Furthermore, this method was validated and applied to the study of tissue distribution of RMP and RTP in mice after RDV administration.

In the current study, we developed a novel sensitive method based on LC-MS/MS for the determination of the mono-and triphosphate types of RDV in mouse tissues. The challenges of weak chromatographic retention, poor stability and high protein affinity were overcome through stepwise fit-for-purpose optimization. The established method was fully validated in terms of linearity, specificity, sensitivity, precision and accuracy and successfully applied to a tissue distribution study of RDV in mice. This method can provide useful information for further study of RDV and may be extended for the determination of a relatively wide group of metabolites that contain mono-and triphosphate groups.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

World Health Organization, WHO Coronavirus Disease (COVID-19) Dashboard

SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

Novel Coronavirus from Patients with Pneumonia in China

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

GS-US-540-5773 Investigators

Food and Drug Administration, Remdesivir for Certain Hospitalized COVID-19 Patients

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease

Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with Pglycoprotein inhibitors

Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

An Antiviral for Treatment of COVID-19, in Healthy Subjects

Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells

Hydrophilic interaction chromatography coupled to tandem mass spectrometry in the presence of hydrophilic ionpairing reagents for the separation of nucleosides and nucleotide mono-, di-and triphosphates

Challenges and solutions in the bioanalysis of BMS-986094 and its metabolites including a highly polar, active nucleoside triphosphate in plasma and tissues using LC-MS/MS

Measurement of intracellular ribavirin mono-, di-and triphosphate using solid phase extraction and LC-MS/MS quantification

Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Optimization of Electrospray Ionization by Statistical Design of Experiments and Response Surface Methodology: Protein-Ligand Equilibrium Dissociation Constant Determinations

Hydrophilic interaction chromatography of nucleoside triphosphates with temperature as a separation parameter

Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS

Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs

Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: a review

Adenosine 5'-triphosphate binding to bovine serum albumin

Simultaneous determination of guanosine and guanosine-5'-triphosphate in biological sample using gold nanoparticles modified indium tin oxide electrode

A fluorescence aptasensor based on two-dimensional sheet metal-organic frameworks for monitoring adenosine triphosphate

Determination of adenosine disodium triphosphate using prulifloxacinterbium(III) as a fluorescence probe by spectrofluorimetry

Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry

A sensitive LC-MS/MS method for quantifying clofarabine triphosphate concentrations in human peripheral blood mononuclear cells

Characterization of enhanced-fluidity liquid hydrophilic interaction chromatography for the separation of nucleosides and nucleotides

Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Quantitation of intracellular triphosphate metabolites of antiretroviral agents in peripheral blood mononuclear cells (PBMCs) and corresponding cell count determinations: review of current methods and challenges

This study was supported by the Youth Innovation Promotion Association of the Chinese Academy of Sciences (2016263) and Shanghai Shuguang Hospital (SGXZ-201907).